 Rachelle Nuss
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 17 | 2023 | 217 | 3.370 |
Why?
| | Hemophilia A | 9 | 2004 | 70 | 1.270 |
Why?
| | Altitude | 5 | 2022 | 409 | 0.990 |
Why?
| | Erythrocyte Transfusion | 4 | 2015 | 187 | 0.880 |
Why?
| | Altitude Sickness | 1 | 2022 | 152 | 0.730 |
Why?
| | Coronavirus | 1 | 2020 | 40 | 0.680 |
Why?
| | Thrombocytopenia | 1 | 2021 | 175 | 0.670 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 79 | 0.670 |
Why?
| | Hemoglobins | 7 | 2021 | 312 | 0.620 |
Why?
| | Hemoglobin SC Disease | 2 | 2015 | 15 | 0.590 |
Why?
| | Sickle Cell Trait | 2 | 2014 | 14 | 0.580 |
Why?
| | Vitreous Hemorrhage | 1 | 2015 | 6 | 0.500 |
Why?
| | Splenic Infarction | 1 | 2014 | 2 | 0.490 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 344 | 0.490 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.490 |
Why?
| | Antiviral Agents | 1 | 2020 | 649 | 0.480 |
Why?
| | Retinal Diseases | 1 | 2015 | 77 | 0.470 |
Why?
| | Pandemics | 2 | 2023 | 1334 | 0.430 |
Why?
| | Thrombosis | 8 | 1998 | 302 | 0.420 |
Why?
| | Hemarthrosis | 2 | 2003 | 11 | 0.400 |
Why?
| | Joint Diseases | 4 | 2004 | 59 | 0.380 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2011 | 99 | 0.380 |
Why?
| | Child | 26 | 2023 | 18487 | 0.330 |
Why?
| | Catheters, Indwelling | 2 | 2008 | 79 | 0.320 |
Why?
| | Echocardiography | 1 | 2011 | 559 | 0.320 |
Why?
| | Catheterization, Central Venous | 2 | 2008 | 81 | 0.310 |
Why?
| | Hypertension, Pulmonary | 4 | 2019 | 1749 | 0.290 |
Why?
| | Peptide Fragments | 1 | 2011 | 675 | 0.290 |
Why?
| | Humans | 51 | 2023 | 115613 | 0.260 |
Why?
| | Adolescent | 19 | 2021 | 17903 | 0.250 |
Why?
| | Physical Exertion | 2 | 2018 | 206 | 0.250 |
Why?
| | Pain | 3 | 2023 | 712 | 0.230 |
Why?
| | beta-Thalassemia | 1 | 2023 | 23 | 0.220 |
Why?
| | Male | 33 | 2023 | 55968 | 0.200 |
Why?
| | Abdominal Pain | 2 | 2014 | 135 | 0.200 |
Why?
| | Child, Preschool | 15 | 2014 | 9131 | 0.200 |
Why?
| | Medical Audit | 1 | 2002 | 75 | 0.200 |
Why?
| | Hemopexin | 1 | 2021 | 13 | 0.200 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 83 | 0.190 |
Why?
| | Lupus Coagulation Inhibitor | 3 | 1996 | 5 | 0.190 |
Why?
| | Hodgkin Disease | 1 | 2023 | 118 | 0.190 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 125 | 0.190 |
Why?
| | Poloxamer | 1 | 2021 | 12 | 0.190 |
Why?
| | Travel | 1 | 2022 | 121 | 0.190 |
Why?
| | Phosphorus Radioisotopes | 1 | 2000 | 28 | 0.190 |
Why?
| | Factor V | 5 | 1998 | 22 | 0.180 |
Why?
| | Protein C | 4 | 1998 | 44 | 0.180 |
Why?
| | Health Care Surveys | 2 | 2002 | 538 | 0.180 |
Why?
| | Vascular Remodeling | 2 | 2019 | 151 | 0.180 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 269 | 0.170 |
Why?
| | Femur Head Necrosis | 1 | 1999 | 9 | 0.170 |
Why?
| | Anticoagulants | 2 | 2020 | 549 | 0.160 |
Why?
| | Vasodilator Agents | 1 | 2021 | 308 | 0.160 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 279 | 0.160 |
Why?
| | Pulmonary Embolism | 3 | 2000 | 182 | 0.160 |
Why?
| | Antibodies, Antiphospholipid | 2 | 1997 | 21 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.140 |
Why?
| | Blood Coagulation Factors | 1 | 1997 | 44 | 0.140 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 30 | 0.140 |
Why?
| | Macrophages | 2 | 2023 | 1284 | 0.140 |
Why?
| | Colorado | 5 | 2014 | 4116 | 0.140 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 1995 | 14 | 0.130 |
Why?
| | Hypoxia | 2 | 2019 | 937 | 0.130 |
Why?
| | Lung | 3 | 2018 | 3673 | 0.130 |
Why?
| | Hemostasis | 1 | 1995 | 67 | 0.130 |
Why?
| | Haptoglobins | 1 | 2015 | 47 | 0.120 |
Why?
| | Pulmonary Artery | 2 | 2019 | 1031 | 0.120 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 1829 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1016 | 0.120 |
Why?
| | Renal Veins | 1 | 1994 | 9 | 0.120 |
Why?
| | Radiography | 3 | 2003 | 826 | 0.120 |
Why?
| | Endothelium, Vascular | 2 | 2018 | 845 | 0.120 |
Why?
| | Adult | 13 | 2023 | 30726 | 0.120 |
Why?
| | Syndrome | 1 | 2014 | 339 | 0.110 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1993 | 25 | 0.110 |
Why?
| | Heart Function Tests | 1 | 1993 | 59 | 0.110 |
Why?
| | Female | 23 | 2023 | 59932 | 0.110 |
Why?
| | Vaccination | 1 | 2021 | 1210 | 0.110 |
Why?
| | Young Adult | 5 | 2021 | 10487 | 0.110 |
Why?
| | Hearing Loss, Sensorineural | 1 | 1993 | 58 | 0.110 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 90 | 0.110 |
Why?
| | Heparin | 1 | 1994 | 227 | 0.100 |
Why?
| | Infant | 13 | 2011 | 7976 | 0.100 |
Why?
| | Hemorrhage | 3 | 2004 | 618 | 0.100 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 1992 | 16 | 0.100 |
Why?
| | Fever | 1 | 1993 | 280 | 0.100 |
Why?
| | Respiratory Function Tests | 1 | 1993 | 535 | 0.100 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2011 | 19 | 0.100 |
Why?
| | Acute Chest Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
| | Phospholipases A2, Secretory | 1 | 2011 | 23 | 0.100 |
Why?
| | Splenomegaly | 1 | 2011 | 18 | 0.100 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2011 | 18 | 0.090 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2011 | 16 | 0.090 |
Why?
| | Nitric Oxide | 2 | 2018 | 832 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 5 | 2004 | 3071 | 0.090 |
Why?
| | Isoantigens | 1 | 2010 | 17 | 0.090 |
Why?
| | Blood Flow Velocity | 1 | 2011 | 324 | 0.090 |
Why?
| | Prospective Studies | 4 | 2014 | 6264 | 0.080 |
Why?
| | Histocompatibility Antigens | 1 | 2010 | 100 | 0.080 |
Why?
| | Spleen | 1 | 1991 | 492 | 0.080 |
Why?
| | Erythrocytes | 2 | 2011 | 589 | 0.080 |
Why?
| | Partial Thromboplastin Time | 3 | 1998 | 51 | 0.080 |
Why?
| | Hemolysis | 2 | 2021 | 146 | 0.080 |
Why?
| | Disease Progression | 3 | 2023 | 2418 | 0.080 |
Why?
| | Endothelial Cells | 1 | 2013 | 695 | 0.080 |
Why?
| | Subclavian Vein | 1 | 2008 | 13 | 0.080 |
Why?
| | Blood Component Removal | 1 | 2008 | 30 | 0.070 |
Why?
| | Blood Coagulation Tests | 3 | 2002 | 57 | 0.070 |
Why?
| | Protein S Deficiency | 2 | 1996 | 6 | 0.070 |
Why?
| | Neutrophils | 1 | 2011 | 1172 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2023 | 12608 | 0.060 |
Why?
| | Point Mutation | 3 | 2003 | 217 | 0.060 |
Why?
| | Prognosis | 2 | 2011 | 3339 | 0.060 |
Why?
| | Prothrombin | 2 | 2003 | 22 | 0.060 |
Why?
| | Hypoprothrombinemias | 1 | 2003 | 3 | 0.060 |
Why?
| | Animals | 6 | 2023 | 32102 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2021 | 1659 | 0.060 |
Why?
| | X-Rays | 1 | 2003 | 31 | 0.050 |
Why?
| | Synovitis | 1 | 2003 | 24 | 0.050 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2002 | 10 | 0.050 |
Why?
| | Thrombin | 1 | 2023 | 141 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2003 | 296 | 0.050 |
Why?
| | Hemostatics | 1 | 2002 | 48 | 0.050 |
Why?
| | Heme | 1 | 2021 | 56 | 0.050 |
Why?
| | Biomarkers | 1 | 2011 | 3468 | 0.050 |
Why?
| | Medical Records | 1 | 2002 | 157 | 0.050 |
Why?
| | Cartilage | 1 | 2003 | 182 | 0.050 |
Why?
| | Medication Errors | 1 | 2002 | 89 | 0.050 |
Why?
| | Oxidation-Reduction | 2 | 2015 | 924 | 0.050 |
Why?
| | Mice | 3 | 2023 | 15052 | 0.050 |
Why?
| | Placebos | 1 | 2021 | 197 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 501 | 0.050 |
Why?
| | Monocytes | 1 | 2023 | 507 | 0.050 |
Why?
| | Documentation | 1 | 2002 | 169 | 0.040 |
Why?
| | Hemorrhagic Disorders | 1 | 2000 | 5 | 0.040 |
Why?
| | Otitis Media | 2 | 1992 | 142 | 0.040 |
Why?
| | Mutation | 4 | 1997 | 3364 | 0.040 |
Why?
| | Antithrombin III Deficiency | 2 | 1998 | 3 | 0.040 |
Why?
| | Cartilage, Articular | 1 | 2003 | 291 | 0.040 |
Why?
| | Thrombolytic Therapy | 1 | 2000 | 118 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 78 | 0.040 |
Why?
| | Lipids | 1 | 2023 | 588 | 0.040 |
Why?
| | Rats | 2 | 2019 | 5034 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2651 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 61 | 0.040 |
Why?
| | Venous Thrombosis | 1 | 2000 | 145 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 4773 | 0.040 |
Why?
| | Hip Joint | 1 | 1999 | 131 | 0.040 |
Why?
| | Patient Readmission | 1 | 2023 | 609 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2019 | 3580 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2000 | 233 | 0.040 |
Why?
| | Blood Coagulation | 2 | 1998 | 221 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 859 | 0.040 |
Why?
| | Protein S | 1 | 1997 | 6 | 0.040 |
Why?
| | Age Factors | 2 | 1995 | 2907 | 0.040 |
Why?
| | Patient Discharge | 1 | 2023 | 770 | 0.040 |
Why?
| | Acclimatization | 1 | 2018 | 132 | 0.040 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 19 | 0.040 |
Why?
| | Proteins | 1 | 2023 | 920 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2017 | 138 | 0.030 |
Why?
| | Ultrasonography | 2 | 2000 | 642 | 0.030 |
Why?
| | Protein C Deficiency | 1 | 1995 | 2 | 0.030 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1995 | 6 | 0.030 |
Why?
| | Amoxicillin | 2 | 1992 | 20 | 0.030 |
Why?
| | Infant, Newborn | 2 | 1997 | 5060 | 0.030 |
Why?
| | Chickenpox | 1 | 1996 | 94 | 0.030 |
Why?
| | Antiphospholipid Syndrome | 1 | 1995 | 26 | 0.030 |
Why?
| | Factor IX | 1 | 1994 | 33 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 1998 | 585 | 0.030 |
Why?
| | Factor VIII | 1 | 1994 | 54 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 155 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 142 | 0.030 |
Why?
| | Warfarin | 1 | 1995 | 136 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 420 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 2987 | 0.030 |
Why?
| | Hearing Loss, Bilateral | 1 | 1993 | 14 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 783 | 0.030 |
Why?
| | Death, Sudden | 1 | 1993 | 33 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2015 | 338 | 0.030 |
Why?
| | Catalase | 1 | 2013 | 118 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 83 | 0.030 |
Why?
| | Iron | 1 | 2015 | 235 | 0.030 |
Why?
| | Permeability | 1 | 2013 | 150 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2017 | 677 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1995 | 221 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2500 | 0.030 |
Why?
| | Blood Pressure | 1 | 2018 | 1537 | 0.030 |
Why?
| | Vascular Diseases | 1 | 2015 | 230 | 0.030 |
Why?
| | Reference Values | 1 | 1993 | 744 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 249 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 357 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 225 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 1998 | 844 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 332 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1991 | 121 | 0.020 |
Why?
| | Splenectomy | 1 | 2011 | 54 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 285 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 1993 | 573 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2011 | 115 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 2604 | 0.020 |
Why?
| | Otitis Media with Effusion | 1 | 1990 | 21 | 0.020 |
Why?
| | Electrocardiography | 1 | 1993 | 560 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 820 | 0.020 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1990 | 39 | 0.020 |
Why?
| | Sex Factors | 1 | 1995 | 1737 | 0.020 |
Why?
| | Heart Rate | 1 | 1993 | 701 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2000 | 4440 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 639 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2194 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2262 | 0.020 |
Why?
| | Postpartum Period | 1 | 1992 | 281 | 0.020 |
Why?
| | Prednisone | 1 | 1990 | 232 | 0.020 |
Why?
| | Pneumonia | 1 | 2015 | 576 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2011 | 644 | 0.020 |
Why?
| | Prevalence | 1 | 1995 | 2265 | 0.020 |
Why?
| | Incidence | 1 | 1995 | 2335 | 0.020 |
Why?
| | Pain Measurement | 1 | 2011 | 449 | 0.020 |
Why?
| | Drug Therapy, Combination | 3 | 2000 | 962 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 1992 | 781 | 0.020 |
Why?
| | Lung Diseases | 1 | 2015 | 710 | 0.020 |
Why?
| | Algorithms | 1 | 1995 | 1491 | 0.020 |
Why?
| | Amino Acid Substitution | 2 | 2000 | 267 | 0.020 |
Why?
| | Kidney | 1 | 1994 | 1207 | 0.020 |
Why?
| | Risk Factors | 3 | 1996 | 8699 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 1998 | 4668 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2013 | 2574 | 0.020 |
Why?
| | Joints | 1 | 2004 | 84 | 0.010 |
Why?
| | International Cooperation | 1 | 2004 | 174 | 0.010 |
Why?
| | Puerto Rico | 1 | 2003 | 52 | 0.010 |
Why?
| | Exercise | 1 | 1993 | 1609 | 0.010 |
Why?
| | Liver | 1 | 1991 | 1690 | 0.010 |
Why?
| | Neoplasms | 1 | 1997 | 2118 | 0.010 |
Why?
| | Homozygote | 1 | 2003 | 186 | 0.010 |
Why?
| | Physical Examination | 1 | 2004 | 222 | 0.010 |
Why?
| | Heterozygote | 1 | 2003 | 252 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2011 | 9159 | 0.010 |
Why?
| | Family Health | 1 | 2003 | 195 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2003 | 372 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2392 | 0.010 |
Why?
| | Signal Transduction | 1 | 2013 | 4541 | 0.010 |
Why?
| | Protein Conformation | 1 | 2003 | 822 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6165 | 0.010 |
Why?
| | Aged | 1 | 1998 | 19255 | 0.010 |
Why?
| | Pregnancy | 1 | 1992 | 5550 | 0.010 |
Why?
| | Plethysmography | 1 | 2000 | 103 | 0.010 |
Why?
| | Recurrence | 2 | 1992 | 952 | 0.010 |
Why?
| | Case-Control Studies | 2 | 1996 | 3023 | 0.010 |
Why?
| | Middle Aged | 1 | 1998 | 27014 | 0.010 |
Why?
| | Drug Resistance | 1 | 1997 | 162 | 0.010 |
Why?
| | Blotting, Western | 1 | 2000 | 1153 | 0.010 |
Why?
| | Arginine | 1 | 1997 | 241 | 0.010 |
Why?
| | Thromboembolism | 1 | 1997 | 93 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2003 | 1919 | 0.010 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 1996 | 30 | 0.010 |
Why?
| | Streptococcus pyogenes | 1 | 1996 | 33 | 0.010 |
Why?
| | Base Sequence | 1 | 2000 | 2114 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2000 | 2790 | 0.010 |
Why?
| | Pedigree | 1 | 1996 | 467 | 0.010 |
Why?
| | Blood Coagulation Disorders | 1 | 1997 | 196 | 0.010 |
Why?
| | Streptococcal Infections | 1 | 1996 | 132 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1997 | 1001 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 795 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1994 | 374 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1997 | 1718 | 0.010 |
Why?
| | IgG Deficiency | 1 | 1992 | 8 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1994 | 548 | 0.010 |
Why?
| | Middle Ear Ventilation | 1 | 1990 | 10 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1994 | 1870 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 1992 | 724 | 0.010 |
Why?
| | Chronic Disease | 1 | 1990 | 1598 | 0.000 |
Why?
|
|
Nuss's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|